Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study

INTRODUCTION: There are no disease-modifying treatments for Parkinson’s disease (PD). We undertook the first drug screen in PD patient tissue and idntified ursodeoxycholic acid (UDCA) as a promising mitochondrial rescue agent. The aims of this trial are to determine safety and tolerability of UDCA i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Payne, Thomas, Sassani, Matilde, Buckley, Ellen, Moll, Sarah, Anton, Adriana, Appleby, Matthew, Maru, Seema, Taylor, Rosie, McNeill, Alisdair, Hoggard, N, Mazza, Claudia, Wilkinson, Iain D, Jenkins, Thomas, Foltynie, Thomas, Bandmann, O
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Neurology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7409998/
https://ncbi.nlm.nih.gov/pubmed/32759251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-038911
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars